D eep vein thrombosis (DVT) is the third most common cause of cardiovascular morbidity and mortality after coronary artery disease and stroke, 1 with an incidence of 1.0 per 1000 population per year. 2, 3 The mortality rates are 4× higher than matched cohorts without DVT. 4 Inferior vena cava (IVC) thrombosis occurs in 2.6% to 4.0% 5, 6 of patients with lower extremity DVT and has a mortality rate twice as high as those with DVT that is confined to the lower extremities. 5 Post-thrombotic syndrome (PTS) develops in 20% to 50% of proximal DVT patients despite standard therapy with anticoagulation and compression stockings. [6] [7] [8] The rate of PTS among patients with IVC thrombosis is unknown. Because the majority of these patients have thrombus extension into iliofemoral veins, 9 PTS rates are expected to be at least similar, if not higher, than in patients with iliofemoral DVT.
Thrombus removal with catheter-directed thrombolysis (CDT) in patients with proximal DVT has been shown to reduce the incidence of PTS and improve quality of life parameters. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although IVC thrombosis is classified under proximal DVTs, these studies rarely included patients with IVC thrombosis. Although the results of these studies suggested a benefit of CDT in preventing PTS, the comparative safety outcomes are inconclusive because of the small number of patients enrolled. This has led to conflicting societal guidelines from the American Heart Association and American College of Chest Physicians 21, 22 with regards to the use of CDT in patients with proximal DVT and without any specific recommendations in patients with IVC thrombosis. We sought to compare inhospital safety outcomes of CDT plus anticoagulation versus anticoagulation alone using risk-adjusted propensity score matching in patients with IVC thrombosis. We also evaluated the temporal trends in the utilization rates and outcomes of CDT in these patients in the United States.
Methods

Study Data
The study data were obtained from the Agency for Healthcare Research and Quality-Nationwide Inpatient Sample (NIS) files between January 2005 and December 2011. Institutional review board approval was obtained. The authors designed the study and are responsible for analyzing the data and for the accuracy of the analysis presented. The NIS is an all-payer, administrative claims-based database, which contains information about patient discharges from ≈1000 nonfederal hospitals in 45 states. The NIS contains clinical and resource utilization information on 5 to 8 million discharges annually, with safeguards to protect the privacy of individual patients, physicians, and hospitals. These data represent 20% of US inpatient hospitalizations stratified across different hospital types including hospital ownership, patient volume, teaching status, urban or rural location, and geographic region. Using an Agency for Healthcare Research and Quality sampling and weighting method, the data were used to calculate national estimates of the entire US hospitalized population. 23 
Study Population
Patients with a principal discharge diagnosis of IVC thrombosis (International Classification of Diseases-Ninth Revision-Clinical
Modification [ICD-9-CM], 453.2) were identified in the NIS database. These patients were stratified according to the use of thrombolytic therapy (ICD-9-CM procedure code, 99.10). Because systemic thrombolysis is rarely used in the treatment of caval DVT, and we excluded patients with a principle discharge diagnosis of pulmonary embolism (PE; ICD-9-CM, 415.1), we hypothesized that the patients who had IVC thrombosis and received thrombolytic therapy were treated with CDT plus anticoagulation. We compared baseline characteristics of this group with patients who did not receive thrombolytics, and we assumed that patients in this group were treated with anticoagulation alone. All data used for trend analysis were derived from national weighted estimates. We excluded patients aged <18 years or if age was missing. We did not include patients diagnosed with proximal lower extremity DVT only (ICD-9-CM, 453.41), isolated distal lower extremity DVT (ICD-9-CM, 453.42), pregnancy-related DVT (ICD-9-CM, 671.3, 671.4, and 671.9), or unspecified lower extremity DVT (ICD-9-CM, 453.40). The outcomes of CDT versus anticoagulation alone in patients with proximal DVT without IVC thrombosis (ICD-9-CM, 453.41) were also evaluated.
Comparative Outcomes Analysis
We anticipated that the CDT group would be different from the anticoagulation group with respect to comorbid and demographic characteristics. To adjust for these confounding variables and to reduce the effect of selection and indication bias, we used propensity matching to derive 2 matched groups for comparative outcomes analysis. A nearest neighbor 1:1 variable ratio, parallel, balanced propensity matching method with a caliper width of 0.01 was used after generating the propensity scores from 44 clinical, hospital, and demographic variables including the Elixhauser Comorbidity Index [24] [25] [26] (Table 1 ). Propensity score matching was performed without replacement given the large number of control patients available for matching with treatment patients. The primary end point was inhospital mortality. Secondary end points were intracranial bleeding, PE, blood transfusion, gastrointestinal bleeding, procedure-related hematomas, IVC filter placement, length of stay, and hospital charges.
Statistical Analysis
Descriptive summary statistics are presented as mean values with SDs for continuous variables and frequencies with percentages for categorical variables. Baseline characteristics were compared between the 2 groups using an independent sample t test for continuous variables and by Pearson χ 2 test for categorical variables. We evaluated
WHAT IS KNOWN
• The inferior vena cava thrombosis occurs in 2.6% to 4.0% of patients with lower extremity deep vein thrombosis with high post-thrombotic syndrome rates despite standard therapy with anticoagulation and compression stockings.
• Thrombus removal with catheter-directed thrombolysis (CDT) in patients with proximal deep vein thrombosis has been shown to reduce the incidence of post-thrombotic syndrome and improve quality of life parameters.
WHAT THE STUDY ADDS
• In the United States, 27% of patients with inferior vena cava thrombosis are treated CDT, with a steady increase in the utilization rates from 16% in 2005 to 34.7% in 2011.
• There was no significant difference in the inhospital mortality between the CDT and the anticoagulation groups; however, the bleeding rates continue to be higher with CDT.
• CDT was also associated with higher upfront resource utilization in terms of increased length of stay and hospital charges. trends in the utilization and outcomes of these 2 treatment strategies using the Cochran-Armitage trend test. Most categorical variables including sex, hospital location, and teaching status had <1% missing data and were imputed to the most common category, except for race which was missing in 19.1%. To preserve the full sample size, we used a dummy variable adjustment method. 27 We used multivariate logistic regression to estimate odds ratios and 95% confidence intervals for the association between CDT use and each end point as compared with the propensity-matched anticoagulation group. To account for immortal time bias, we used a Cox regression model using the procedure day of CDT as a time-dependent covariate for the primary end point of death. 28 We also performed our comparative safety analysis with the following methods: (1) 1:5 nearest neighbor matching and (2) propensity score-adjusted logistic regression analysis. Finally, we used a rule-out approach for sensitivity analysis 29 to illustrate how strongly a single unmeasured binary confounder would have to be associated with both CDT use and the end point to fully explain our significant findings. All statistical analyses were performed using SPSS version 22 (IBM) and SAS version 9.3 (Cary, NC).
Results
Characteristics of the Study Population
Among a total of 2674 patients admitted with IVC thrombosis, 26.9% (718) underwent CDT between January-2005 and December-2011. This represented a national estimate of 13 370 total cases of IVC thrombosis with 3590 patients who underwent CDT (Figure 1 ). The baseline characteristics of these patients are shown in Table 2 .
Trends in the Utilization of CDT
A steady increase in CDT utilization was noted during the 7-year study period from 16% in 2005 to 34.7% in 2011 (Figure 2 ). The majority (94.8%) of CDT procedures were done within first 6 days of hospitalization with a median procedure day of 1.0 and a mean procedure day of 2.0. The groups that were less likely to be treated with thrombolysis included women (22.4% versus 31.7%; P<0.001) and blacks (21.2% versus 29.1%; P<0.001) when compared with men and whites, respectively. Patients with private third-party insurance had higher CDT rates than Medicare and Medicaid patients (34.8% versus 19.2% versus 11.3%; P<0.001). CDT was more likely to be performed in urban (28.2% versus 12.2%; P<0.001) and academic centers (28.4% versus 24.9%; P<0.001) compared with rural and nonacademic centers, respectively. In the CDT group, 59.2% of patients underwent balloon angioplasty and 21.9% had stenting. The rates of adverse outcomes in the 2 treatment groups did not change significantly during the study period; however, hospital charges did increase (Figure 3) .
During the study period (2005-2011), a total of 105 569 patients in the NIS database were diagnosed with proximal DVT without IVC thrombosis. Among these patients, 4108 underwent CDT. 
Characteristics and Outcomes of Propensity-Matched Groups
The propensity score-matching algorithm yielded 563 wellmatched patients in each group with a c-statistic of 0.79. Baseline characteristics are shown in Table 2 and the inhospital clinical outcomes are shown in Table 3 . There was no statistically significant difference in the inhospital mortality between the CDT and the anticoagulation groups (2.0% versus 1.4%; odds ratio, 1.38; 95% confidence interval, 0.55-3.46; P=0.49; Figure 4 ). Compared with the anticoagulation group, the rates of PE (12.1% versus 7.8%; P=0.02), intracranial hemorrhage (1.6% versus 0.2%; P=0.03), and acute renal failure (13.9% versus 9.4%; P=0.02) were significantly higher in the CDT group. Gastrointestinal bleeding was lower in the CDT group (1.2% versus 3.4%; odds ratio, 0.36, 95% confidence interval, 0.15-0.86; P=0.02). There was no significant difference in the IVC filters placement rates between the CDT group (21.3%) and the anticoagulation group (20.2%; odds ratio, 1.07; 95% confidence interval, 0.8-1.42; P=0.66; Table 3 ). The use of CDT was associated with longer length of stay (8.1±6.4 versus 6.9±7.2 days; P<0.001) and higher hospital charges ($103 164±91 494 versus $50 689±69 960; P<0.001) when compared with anticoagulation alone ( Table 4 ). The inhospital outcomes of CDT versus anticoagulation alone in the unmatched groups are presented in Table I in the Data Supplement. In noncaval DVT patients, CDT group had similar mortality but higher morbidity compared with those treated with anticoagulation alone (Table II in 
Sensitivity Analysis
Using the rule-out approach, we estimated that for an unmeasured confounder to fully explain our estimates in acute kidney injury rates and CDT use, the confounder has to be 3× more prevalent in CDT than in anticoagulation group and would itself have to increase the acute kidney injury risk by 6-fold. For all other outcomes used in Table 3 , only under similar or even more extreme conditions could the results be fully explained by an unmeasured confounder. Our results were similar in all the other comparative analytic methods used including a Cox regression model with a time-dependent covariate, 1:5 nearest neighbor matching, propensity score-adjusted logistic regression analysis. The outcomes after adjusting for all key baseline characteristics are presented in Table III in the Data Supplement and outcomes derived from a Cox regression model using the procedure day of CDT as a time-dependent covariate are presented in Table IV in the Data Supplement.
Discussion
This is the first nationwide observational study that describes contemporary trends in the utilization and comparative safety outcomes of CDT in patients with IVC thrombosis. CDT utilization rates in all patients admitted with proximal DVT have increased from 2.3% in 2005 to 6.4% in 2011. 30 However, the utilization rate of CDT in patients with IVC thrombosis has not been previously reported. We found a 2-fold increase in the CDT utilization in the treatment of these patients from 2005 to 2011 ( Figure 2) . These data suggest an increasing adoption of CDT to treat IVC thrombosis despite the lack of guidelinebased recommendations or randomized trial evidence.
The main goal of CDT use in patients with proximal DVT is to reduce the risk of developing PTS. The Catheter-Directed Venous Thrombolysis (CaVenT) trial showed that CDT was associated with 14.4% absolute risk reduction of PTS at 24 months of follow-up in patients with iliofemoral DVT compared with anticoagulation alone. 31 Major concerns with CDT are the higher risk of bleeding and the complexity of the procedure as compared with conventional anticoagulation alone. Although there was no excess of death, PE, or intracranial hemorrhage in the CDT group, major bleeding rate in both the CaVent and the Kolbel study was 8% to 9%, raising concerns about safety of CDT. 20, 30 Even Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT), the largest ongoing randomized CDT trial, may not have large enough sample size to address the safety concern of CDT because of the low incidence of adverse events. 32 Most importantly, neither the CaVent nor the ATTRACT trial addresses the safety of CDT in patients with IVC thrombosis. Our study is the largest study of IVC thrombosis patients that is sufficiently powered to detect significant differences in acute morbidity and mortality between the 2 treatment strategies. Our propensitymatched comparative effectiveness analysis showed no significant difference in inhospital mortality in the CDT group compared with the anticoagulation alone group. However, CDT use was associated with higher rates of adverse events including intracranial hemorrhage, PE, and acute renal failure.
The American Heart Association guidelines for treatment of iliofemoral DVT recommend a consideration of balloon venoplasty and stenting in patients with residual obstructive lesions after CDT. 21 However, no such specific recommendations have been made with regards to patients with IVC thrombosis. Kölbel et al 20 reported a high rate of balloon venoplasty and stenting (82%) in a series of patients with iliocaval DVT who underwent CDT. Our study also suggests that in real-world practice a large proportion of patients who are treated with CDT are treated with adjunctive balloon venoplasty and stenting (55.6% and 19.7%, respectively). The rationale behind this adjunctive therapy is to avoid the high rates of rethrombosis associated with untreated residual venous obstruction after thrombus removal. Hartung et al 33 showed that venoplasty±stenting in patients with iliac DVT and residual venous obstruction after surgical thrombectomy reduced the rethrombosis rates to 13% compared with 73% for those who were left with untreated residual stenosis (P<0.01). Placement of IVC filters to prevent PE in patients with DVT has been a topic of debate for many years. The current literature and societal guidelines recommend against the routine use of IVC filters. 21, 22, 30, 34 However, the rates of IVC filter placement continue to increase in the United States. 35 There is a continuous effort to identify subsets of patients who may benefit the most from IVC filters such as patients with large clot burden and those at high-risk for bleeding. 36, 37 The utilization rate of IVC filters in patients with IVC thrombosis has not been reported. In our propensity-matched cohort, 21.3% of patients in the CDT group and 20.2% of patients in the anticoagulation group received IVC filters.
Our study also showed that CDT was associated with higher upfront resource utilization in terms of increased length of stay and hospital charges. It is therefore crucial that rigorous economic analyses from ongoing and completed randomized trials are incorporated into future guideline recommendations.
Limitations
The retrospective study design and the data sets identified by
ICD codes is major limitations of this study. 2. The potential for unmeasured confounders may bias the results in either direction. Perhaps patients with larger, more dangerous clots are selected for CDT, or alternatively more stable patients were selected to undergo CDT. However, we think that rigorous propensity matching and sensitivity analyses addressed this selection bias. 3. Accurate quantification of adverse events other than inhospital mortality and blood transfusion rates may be lacking because of coding inaccuracies. However, we think that comparative analysis is fairly reasonable after propensity matching with the potential caveat of overestimating the adverse events like PE in both treatment groups. 4. In an attempt to avoid mixed data, we excluded patients with a primary diagnosis of PE or iliofemoral DVT and only included those with a primary diagnosis of IVC thrombosis. Therefore, our study might underestimate the true number of patients with IVC thrombosis. 5. Our results are based on inhospital administrative claimsbased data. The development of recurrent DVT, the occurrence of PTS, and the long-term mortality data are not available. 6. The physician's approach to patients with IVC thrombosis might have been affected by the availability of local experts in CDT, which may have led to the consideration or the exclusion of CDT as a treatment option. 7. The presence of a prior IVC filter is not reliably captured in this database. Although many of these patients could have had IVC filter thrombosis, we are unable to assess that variable.
Conclusions
This contemporary observational study is the first nationwide study of patients with IVC thrombosis showing a steady increase in CDT utilization rates. CDT was associated with higher morbidity and increased healthcare resource utilization without a significant difference in mortality compared with anticoagulation alone. This highlights the need for larger randomized trials to evaluate the benefit of CDT in the prevention of PTS and recurrence of DVT in patients with IVC thrombosis who do not have an absolute indication for CDT such as phlegmasia cerulea dolens. 
